-
Lennox Gastaut Syndrome Market Research 2025-2035 Featuring UCB, Jazz Pharmaceuticals, GSK, Assertio, Immedica Pharma, Harmony Biosciences, AbbVie, J&J, Mylan, Eisai, and Lundbeck - ResearchAndMarkets.com
31 Jul 2025 14:15 GMT
DUBLIN--(BUSINESS WIRE)--Jul 31, 2025--
×
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
kAm%96 {6??@I 82DE2FE DJ?5C@>6 >2C<6E :D 6IA6C:6?4:?8 D:8?:7:42?E 8C@HE9 5F6 E@ E96 :?4C62D:?8 …
-
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
18 Nov 2025 13:45 GMT
… Zymeworks’ development and commercialization partners, Jazz Pharmaceuticals (Jazz) and BeOne Medicines (BeOne … as Alzheimer's disease (AD) and Parkinson's disease …
-
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
18 Nov 2025 06:00 GMT
Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholders
Strategic initiative follows positive topline results from pivotal Phase 3 HERIZON-GEA-01 trial evaluating zanidatamab in …
-
Traders Strap In, Again
18 Nov 2025 21:36 GMT
… 7% revenue drop from weak advertising demand.
The European Commission has … USD 55 to USD 75.
Jazz Pharmaceuticals Plc: Baird maintains its outperform …
-
US Equity Futures Fade Overnight Gains As Global Selloff Deepens
17 Nov 2025 14:15 GMT
… and esophagus. Shares of partner Jazz Pharmaceuticals (JAZZ) are up 21%.
In … much as 6.7% as advertising agency Havas has expressed interest …
-
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q2 2024 Earnings Call Transcript
01 Aug 2024 13:02 GMT
… did have that larger patient ad in the first quarter that … remarkable about the Xywav narcolepsy ads is that despite having a … now disconnect.
Follow Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) Follow Jazz Pharmaceuticals Plc (NASDAQ:JAZZ …
-
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2024 Earnings Call Transcript
07 May 2024 15:16 GMT
… , and good afternoon, everyone Today, Jazz Pharmaceuticals reported its first quarter 2024 … ;A Session Follow Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) Follow Jazz Pharmaceuticals Plc (NASDAQ:JAZZ … level of difference on the ADS or the performance scale that …
-
HER2+ Market to Accelerate Substantially by 2034, Predicts DelveInsight | Key Companies - Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen Therapeutics, Enliven Therapeutics, Roche
17 Apr 2024 17:00 GMT
New York, USA, April 17, 2024 (GLOBE NEWSWIRE) -- HER2+ Market to Accelerate Substantially by 2034, Predicts DelveInsight | Key Companies - Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen Therapeutics, Enliven Therapeutics, Roche With the improvement of …
-
Lennox-Gastaut Syndrome Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight | Key Players to Watch Out - Zogenix, Epygenix, SK Life Science, Takeda, Jazz Pharmaceuticals, Longboard Pharmaceuticals
05 Oct 2023 17:00 GMT
New York, USA, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Lennox-Gastaut Syndrome Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight | Key Players to Watch Out - Zogenix, Epygenix, SK Life Science, Takeda, Jazz Pharmaceuticals, …
-
Momentum and Value for People of Color (MVP) Announces New Program with Jazz Pharmaceuticals to Develop Talent Pipeline
15 Sep 2023 00:07 GMT
KINNELON, NEW JERSEY, UNITED STATES, September 14, 2023 /EINPresswire.com/ -- MVP (Momentum and Value for People of Color), a nonprofit 501(c)(3) organization committed to creating equity and access to opportunity for young people of color, is …
About
© 1995-2025